A research blog from the NCI Division of Cancer Prevention Subscribe Research Highlights: How Western-Style Diet, Aging, May Impact Cancer Risk in Intestinal Cells October 25, 2023 | By DCP Staff A healthier diet has been associated with reduced risk of cancer, but the mechanisms of how that actually works continue to be investigated. In two recent studies, researchers are looking to understand the process on a molecular level. Research Highlights: Repurposing Common Medications to Prevent Cancer September 11, 2023 | By DCP Staff Two recent publications focus on widely used treatments for other diseases to evaluate possible roles in the prevention of cancer. One looked at the potential of statins, a common heart disease drug, to prevent gynecologic cancers, and the other examined whether metformin, a drug for type 2 diabetes, could reduce the risk for breast cancer development. In both studies, investigators relied on a growing understanding of the anti-cancer mechanisms of each drug to assess efforts to repurpose them for cancer use. Collaboration Spurs Rapid Growth and Progress in Cardio-Oncology Research August 8, 2023 | By DCP Staff Cardio-oncology research looks at cancer treatment-related cardiotoxicity, or damage to the heart and cardiovascular system (including heart valves and vessels) that can occur during or after cancer treatment. Over the last decade, efforts from the National Cancer Institute (NCI) in this area, as well as the field in general, have expanded significantly. U.S. Study Shows HPV Antibodies Remain High Up to 2 Years After a Single Dose of HPV Vaccine July 18, 2023 | By Linda Wang After receiving an initial single dose of the HPV vaccine Gardasil 9, children aged 9 to 11 had high levels of two key antibodies that protect against HPV infections and cancer for up to 2 years before receiving their delayed booster dose, according to results from a clinical trial supported by NCI. Important Symptom Management Findings Presented at 2023 ASCO Meeting June 13, 2023 | By DCP Staff Results from two NCI-supported studies relating to symptom management were among the significant findings presented at the June 2023 ASCO meeting. The findings, which both incorporated data from patient-reported outcomes (PROs), have the potential to help reduce toxic side effects and improve quality of life for people with cancer. Research Highlights: Investigating Associations of Obesity with Colorectal and GI Cancers June 5, 2023 | By DCP Staff An estimated 153,020 men and women in the U.S. will be diagnosed with colorectal cancer in 2023, and 52,550 are expected to die of this disease. In two recent studies, researchers addressed the impact of overweight, obesity, and body mass index (BMI) on colorectal and non-colorectal gastrointestinal (GI) cancers at different stages of adult life, as well as the association of BMI and different molecular subtypes in colorectal cancers. Eliminating Underlying Liver Disease Remains Key Strategy for Liver Cancer Prevention May 4, 2023 | By Susan Jenks Despite intense research, liver cancer prevention remains a challenge. Current efforts are directed at underlying conditions that can significantly raise an individual’s risk, including hepatitis C infection, for which researchers are working to find a vaccine. NCI Supports New Research into Prevention of Early-Onset Colorectal Cancer March 22, 2023 | By Susan Jenks Early-onset colorectal cancer is considered relatively rare, but both incidence and mortality rates are increasing in people under age 50. NCI recently issued a special research request for grant applications–in areas such as risk factors, biomarkers, screening methods, and preventive interventions. Trials Test Vaccines for Prevention or Delay of Cancers Associated with Lynch Syndrome February 8, 2023 | By Susan Jenks Researchers have recruited the first vaccine candidates to one of two new prevention trials that seek to immunize high-risk individuals against cancers associated with Lynch syndrome, the most common cause of hereditary colorectal cancer. Individuals who inherit the condition have an estimated lifetime risk as high as 80% for developing one of these malignancies, as well as an above-average risk for cancers arising in other organs, often at an early age, and regardless of race or gender. NCI Funding Approved to Expand Research on Immunoprevention, Natural Products January 10, 2023 | By DCP Staff The National Cancer Institute’s (NCI’s) Board of Scientific Advisors (BSA) recently approved two new concept proposals aimed at expanding potential prevention interventions. One will strengthen research in the nascent field of immunoprevention, and the other will accelerate the development of novel natural products for intercepting cancer at the earliest stages of disease. Pagination « First First page ‹ Previous Previous page 1 2 3 4 … Next › Next page Last » Last page
